Houston, TXNCT04664179Now EnrollingIRB Ready

EBV-Related Hodgkin Lymphoma Clinical Trial in Houston, TX

Access cutting-edge ebv-related hodgkin lymphoma treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by Baylor College of Medicine

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access ebv-related hodgkin lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ebv-related hodgkin lymphoma treatment provided free

Apply for This Houston Location

Check if you qualify for this ebv-related hodgkin lymphoma clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This EBV-Related Hodgkin Lymphoma Study in Houston

This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment the investigators know for these diseases. Some patients with Lymphoma or T/NK-lymphoproliferative disease show signs of virus that is sometimes called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever ("mono") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with Hodgkin's and non-Hodgkin Lymphoma, suggesting that plays a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. T cells have been used to treat patients with cancers. T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor. The investigators have treated over 80 people on studies using T cells to target these diseases. About half of those patients who had disease at the time they got the cells had responses including some patients with complete responses. The investigators think that if T cells are able to last longer in the body, they may have a better chance of killing EBV and EBV infected tumor cells. Therefore, in this study the investigators will add a new gene to the EBV T cells that can cause the cells to live longer called C7R. The investigators know that T cells need substances called cytokines to survive and the cells may not get enough cytokines after infusion into the body. The investigators have added the gene C7R that gives the cells a constant supply of cytokine and helps them to survive for a longer period of time. The purpose of this study is to find the largest safe dose of C7R-EBV T cells, and additionally to evaluate how long they can be detected in the blood and what affect they have on cancer.

Sponsor: Baylor College of Medicine

Who Can Participate

Inclusion Criteria

AT TIME OF PROCUREMENT
Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)- T/NK-lymphoproliferative disease who may subsequently be eligible for the treatment component
EBV positive tumor (can be pending)
Weighs at least 10 kg
Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given a copy of informed consent.
EBV positive Hodgkin's lymphoma
EBV positive non-Hodgkin's Lymphoma (regardless of histologic subtype)
EBV (associated)-T/NK-lymphoproliferative disease AND either A) In first or subsequent relapse or with persistent active disease despite therapy; OR B) With active disease if immunosuppressive chemotherapy is contraindicated as determined by the study PI, in consultation with the primary provider as needed, e.g. patients who develop Hodgkin's disease after solid organ transplantation or if the lymphoma is a second malignancy, e.g. a Richter's transformation of CLL. 2\) EBV positive tumor confirmed by pathology 3\) Patients with life expectancy ≥ 6 weeks 4\) Patients with bilirubin ≤ 3x upper limit of normal, AST ≤ 3x upper limit of normal, creatinine ≤ 2x upper limit of normal for age and Hgb ≥ 7.0 (may be a transfused value) 5\) Pulse oximetry of \>90% on room air 6\) Patients should have been off other investigational therapy for 4 weeks prior to entry in this study. 7\) Patients with a Karnofsky/Lansky score of ≥ 50 8\) Informed consent explained to, understood and signed by patient/guardian. Patient/guardian given a copy of informed consent. 3.

Exclusion Criteria

AT TIME OF PROCUREMENT 1\. Known pregnancy or actively breastfeeding (pregnancy test is not required at the time of procurement).
Pregnant or breastfeeding
Active and uncontrolled bacterial, viral or fungal infection
Current use of systemic corticosteroids (prednisone equivalent \>0.5 mg/kg/day)
Bulky disease resulting in airway obstruction or risk for airway obstruction with further enlargement.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT04664179) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

EBV-Related Hodgkin Lymphoma Treatment Options in Houston, TX

If you're searching for ebv-related hodgkin lymphoma treatment options in Houston, TX, this clinical trial (NCT04664179) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ebv-related hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ebv-related hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Houston, TX

See all lymphoma clinical trials recruiting in Houston — not just this study.

Browse Lymphoma Trials in Houston

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX